Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)

BACKGROUND: FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab has shown to be one of the therapeutic regimens in first line with the highest activity in patients (pts.) with metastatic colorectal cancer (mCRC) unselected for biomolecular alterations. Generally, tumor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Damato, Angela, Iachetta, Francesco, Antonuzzo, Lorenzo, Nasti, Guglielmo, Bergamo, Francesca, Bordonaro, Roberto, Maiello, Evaristo, Zaniboni, Alberto, Tonini, Giuseppe, Romagnani, Alessandra, Berselli, Annalisa, Normanno, Nicola, Pinto, Carmine
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7457535/
https://ncbi.nlm.nih.gov/pubmed/32867715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07268-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados